Northwest Biotherapeutics, Inc. has announced an agreement to acquire Advent BioServices Ltd. from Toucan Holdings LLC. Upon completion of the transaction, Advent will become a wholly owned subsidiary, allowing Northwest Biotherapeutics to integrate its manufacturing and product development operations internally. This acquisition is expected to enhance operational scalability and yield cost efficiencies. The agreement includes the transfer of Advent's fixed assets and intellectual property to Northwest Biotherapeutics, along with 19 million NWBio securities previously issued to Advent. Payment for the acquisition will be made in installments over two years, starting 90 days post-agreement, with potential acceleration contingent on regulatory approval of the DCVax®-L product.